McCleod, Michael
3 papers on CoChat
Most cited papers
- Verified
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2019) · The Lancet Oncology
Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers
Cited by 1,662
- Verified
Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
Lynch, T. J., Patel, T., Dreisbach, L., McCleod, M., Heim, W. J., Hermann, R. C., Paschold, E., Iannotti, N. O., Dakhil, S., Gorton, S., et al. (2010) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 447
- Verified
IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC
Cappuzzo, F., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2018) · Annals of Oncology
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 57
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free